{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:45Z","timestamp":1793923965500,"version":"4.8.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T00:00:00Z","timestamp":1700784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002567","name":"American Academy of Allergy Asthma and Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002567","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002894","name":"Foundation of the American College of Allergy, Asthma & Immunology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002894","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jaci.2023.08.029","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T04:07:10Z","timestamp":1694232430000},"page":"1470-1492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0201-2630","authenticated-orcid":false,"given":"Alexandro W.L.","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon H.","family":"Guyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"D\u00edaz Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ceccacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene X.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"McMullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archita","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Brignardello-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Izcovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Oykhman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peck Y.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Laura","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"LeBovidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenhawt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna D.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfred T.","family":"Frazier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Ellison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korey","family":"Capozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"De Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Smith Begolka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Asiniwasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda C.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8269-4496","authenticated-orcid":false,"given":"Derek K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.08.029_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaci.2012.12.672","article-title":"Atopic dermatitis: a practice parameter update 2012","volume":"131","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2021.11.006","article-title":"Skin barrier defects in atopic dermatitis: from old idea to new opportunity","volume":"71","author":"Yoshida","year":"2022","journal-title":"Allergol Int"},{"key":"10.1016\/j.jaci.2023.08.029_bib4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.anai.2022.03.024","article-title":"Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE","volume":"128","author":"Bakaa","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2022.09.020","article-title":"Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms","volume":"151","author":"Yepes-Nunez","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib7","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.jaip.2022.06.044","article-title":"Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"10","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.029_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/pai.13104","article-title":"Are avoidance diets still warranted in children with atopic dermatitis?","volume":"31","author":"Eigenmann","year":"2020","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/jdv.18919","article-title":"Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: a systematic review and meta-analysis","volume":"37","author":"Christensen","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2023.08.029_bib12","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.2075","article-title":"Comparative efficacy and safety of monoclonal antibodies and Janus kinase inhibitors in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"102","author":"Sedeh","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib15","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane","year":"2021"},{"key":"10.1016\/j.jaci.2023.08.029_bib16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib17","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1016\/j.jaip.2021.09.035","article-title":"Translating evidence to optimize patient care using GRADE","volume":"9","author":"Chu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.029_bib18","article-title":"A guide and pragmatic considerations for applying GRADE to network meta-analysis","volume":"381","author":"Izcovich","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib21","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1016\/j.jaip.2022.06.017","article-title":"Trustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future","volume":"10","author":"Agarwal","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.029_bib22","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamapediatrics.2022.3109","article-title":"What parents should know about atopic dermatitis","volume":"176","author":"Wheeler","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaci.2023.08.029_bib23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jaci.2023.08.029_bib24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamadermatol.2022.6045","article-title":"Values and preferences of patients and caregivers regarding treatment of atopic dermatitis (eczema): a systematic review","volume":"159","author":"Maleki-Yazdi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib25","first-page":"CD011224","article-title":"Leukotriene receptor antagonists for eczema","volume":"10","author":"Ferguson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2023.08.029_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2014publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib27","doi-asserted-by":"crossref","first-page":"n2231","DOI":"10.1136\/bmj.n2231","article-title":"Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis","volume":"374","author":"Siemieniuk","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib28","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib29","first-page":"m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib30","doi-asserted-by":"crossref","first-page":"n526","DOI":"10.1136\/bmj.n526","article-title":"A living WHO guideline on drugs to prevent covid-19","volume":"372","author":"Lamontagne","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib31","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12874-018-0483-0","article-title":"Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review","volume":"18","author":"Weir","year":"2018","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jaci.2023.08.029_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/jrsm.1429","article-title":"Optimally estimating the sample standard deviation from the five-number summary","volume":"11","author":"Shi","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jaci.2023.08.029_bib34","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jrsm.46","article-title":"Pooling health-related quality of life outcomes in meta-analysis\u2014a tutorial and review of methods for enhancing interpretability","volume":"2","author":"Thorlund","year":"2011","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jaci.2023.08.029_bib37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib39","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME Core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jaad.2016.05.043","article-title":"Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review","volume":"75","author":"Barbarot","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib41","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/archderm.142.9.1190","article-title":"What is meant by a \u201cflare\u201d in atopic dermatitis? A\u00a0systematic review and proposal","volume":"142","author":"Langan","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124770","article-title":"Validation of treatment escalation as a definition of atopic eczema flares","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.08.029_bib43","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","article-title":"GRADE guidelines: 7. Rating the quality of evidence\u2014inconsistency","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib44","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE guidelines: 12. Preparing summary of findings tables\u2014binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib47","doi-asserted-by":"crossref","first-page":"n949","DOI":"10.1136\/bmj.n949","article-title":"Prophylaxis against covid-19: living systematic review and network meta-analysis","volume":"373","author":"Bartoszko","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2023.06.010","article-title":"GRADE Working Group. Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis","volume":"160","author":"Brignardello-Petersen","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib49","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib50","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jclinepi.2021.07.011","article-title":"GRADE guidelines 33: addressing imprecision in a network meta-analysis","volume":"139","author":"Brignardello-Petersen","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jclinepi.2018.11.025","article-title":"GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence","volume":"108","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib53","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jclinepi.2017.10.005","article-title":"Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis","volume":"93","author":"Brignardello-Petersen","year":"2018","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib54","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13609","article-title":"Method\u2019s corner: allergist\u2019s guide to network meta-analysis","volume":"33","author":"Chu","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","article-title":"GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings","volume":"137","author":"Zeng","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.7326\/M15-2521","article-title":"Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials","volume":"164","author":"Trinquart","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib58","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib59","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib60","first-page":"139","article-title":"High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis","volume":"4","author":"Bemanian","year":"2005","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib62","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib63","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib64","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib66","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","article-title":"Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"80","author":"Blauvelt","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib67","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamapediatrics.2019.4476","article-title":"Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial","volume":"174","author":"Chan","year":"2020","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaci.2023.08.029_bib69","first-page":"653","article-title":"A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life","volume":"42","author":"Czech","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib70","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib71","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s001050051336","article-title":"UVA1 phototherapy. Pilot study of dose finding in acute exacerbated atopic dermatitis [in German]","volume":"52","author":"Dittmar","year":"2001","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaci.2023.08.029_bib72","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib73","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00431-012-1893-3","article-title":"Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt","volume":"172","author":"El-Khalawany","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jaci.2023.08.029_bib74","first-page":"279","article-title":"A double blind clinical trial on the effectiveness of a thymic derivative (thymomodulin) in the treatment of children with atopic dermatitis","volume":"3","author":"Fiocchi","year":"1987","journal-title":"Int J Immunother"},{"key":"10.1016\/j.jaci.2023.08.029_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjd.21092","article-title":"O06: a randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT)","volume":"187","author":"Flohr","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib76","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1111\/j.1365-2222.2007.02811.x","article-title":"A double-blind, placebo-controlled trial of montelukast in adult atopic eczema","volume":"37","author":"Friedmann","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.08.029_bib77","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2008.08984.x","article-title":"Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study","volume":"160","author":"Gambichler","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib78","doi-asserted-by":"crossref","first-page":"2576S","DOI":"10.1093\/jn\/nxaa200","article-title":"l-Histidine supplementation in adults and young children with atopic dermatitis (eczema)","volume":"150","author":"Gibbs","year":"2020","journal-title":"J Nutr"},{"key":"10.1016\/j.jaci.2023.08.029_bib79","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib80","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jaip.2017.07.007","article-title":"Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial","volume":"6","author":"Goujon","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.029_bib81","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/000155501750208137","article-title":"Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis","volume":"81","author":"Granlund","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib84","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib85","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib86","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib87","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib88","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Guttman-Yassky","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib89","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib90","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib91","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A\u00a0as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib92","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0190-9622(93)70026-P","article-title":"Recombinant interferon gamma therapy for atopic dermatitis","volume":"28","author":"Hanifin","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib93","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1365-2133.2000.03241.x","article-title":"Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy","volume":"142","author":"Harper","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib94","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.1991.tb14174.x","article-title":"A double-blind placebo-controlled study of thymostimulin (TP-1) for the treatment of atopic eczema","volume":"125","author":"Harper","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib95","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.289.6446.651","article-title":"Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: a randomised controlled trial","volume":"289","author":"Heddle","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.jaci.2023.08.029_bib96","first-page":"990","article-title":"Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course\u2014a randomized, placebo-controlled and double blind pilot study","volume":"8","author":"Heil","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaci.2023.08.029_bib97","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1468-3083.2010.03857.x","article-title":"A first prospective randomized controlled trial on the efficacy and safety of synchronous balneophototherapy vs. narrow-band UVB monotherapy for atopic dermatitis","volume":"25","author":"Heinlin","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib98","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/adc.67.9.1095","article-title":"Thymopentin treatment in severe atopic dermatitis\u2014clinical and immunological evaluations","volume":"67","author":"Hsieh","year":"1992","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2023.08.029_bib99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000350486","article-title":"Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial","volume":"162","author":"Iyengar","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib100","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1067\/mjd.2000.104793","article-title":"Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma","volume":"42","author":"Jang","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4168\/aair.2011.3.2.89","article-title":"Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis","volume":"3","author":"Jee","year":"2011","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2023.08.029_bib102","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4168\/aair.2016.8.4.305","article-title":"Pyun BY. A\u00a0double-blind, randomized, crossover study to compare the effectiveness of montelukast on atopic dermatitis in Korean children","volume":"8","author":"Jeon","year":"2016","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2023.08.029_bib103","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/dth.12163","article-title":"Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial","volume":"28","author":"Jin","year":"2015","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2023.08.029_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib105","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/all.14050","article-title":"Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis","volume":"75","author":"Kang","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.029_bib106","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0190-9622(83)70042-3","article-title":"Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis","volume":"8","author":"Kang","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","volume":"6","author":"Katoh","year":"2022","journal-title":"JAAD Int"},{"key":"10.1016\/j.jaci.2023.08.029_bib108","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/exd.13112","article-title":"Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"26","author":"Khattri","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib109","first-page":"33","article-title":"Cyclosporine and extracorporeal photopheresis are equipotent in treating severe atopic dermatitis: a randomized cross-over study comparing two efficient treatment modalities","volume":"1","author":"Koppelhus","year":"2014","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2023.08.029_bib110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0190-9622(92)70031-A","article-title":"High-dose UVA1 therapy in the treatment of patients with atopic dermatitis","volume":"26","author":"Krutmann","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib111","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0190-9622(98)70123-9","article-title":"High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial","volume":"38","author":"Krutmann","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib112","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/1346-8138.12003","article-title":"Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A\u00a0in patients with atopic dermatitis: a pilot study","volume":"40","author":"Kwon","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1203475418805744","article-title":"Vitamin D level and supplementation in pediatric atopic dermatitis: a randomized controlled trial","volume":"23","author":"Lara-Corrales","year":"2019","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.08.029_bib114","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0091-6749(90)90079-J","article-title":"Thymopentin therapy reduces the clinical severity of atopic dermatitis","volume":"85","author":"Leung","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2340\/00015555-2852","article-title":"Substance P antagonist aprepitant shows no additive effect compared with standardized topical treatment alone in patients with atopic dermatitis","volume":"98","author":"Lonndahl","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib116","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.679","article-title":"The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: a randomized controlled trial","volume":"8","author":"Mansour","year":"2020","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.jaci.2023.08.029_bib117","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib118","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib119","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2021.03.032","article-title":"Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"85","author":"Merola","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib120","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jid.2019.03.636","article-title":"560 KPL-716, anti-oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis","volume":"139","author":"Mikhak","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib121","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib122","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib123","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4168\/aair.2020.12.6.949","article-title":"Efficacy, safety, and immunomodulatory effect of the intramuscular administration of autologous total immunoglobulin G for atopic dermatitis: a randomized clinical trial","volume":"12","author":"Nahm","year":"2020","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.jaci.2023.08.029_bib124","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/000155502320323298","article-title":"Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults","volume":"82","author":"Nettis","year":"2002","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib126","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1111\/bcp.14361","article-title":"The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis","volume":"86","author":"Nnane","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2023.08.029_bib127","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1398-9995.2005.00791.x","article-title":"Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis","volume":"60","author":"Oldhoff","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2023.08.029_bib128","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/jdv.15362","article-title":"\u2018High dose\u2019 vs. \u2018medium dose\u2019 UVA1 phototherapy in Italian patients with severe atopic dermatitis","volume":"33","author":"Pacifico","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib129","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1365-2222.2004.1907.x","article-title":"Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: a randomized study","volume":"34","author":"Pacor","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2023.08.029_bib130","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib131","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13530-020-00040-y","article-title":"A clinical study on the efficacy and safety of the exopolymers from Aureobasidium pullulans (EAP) in subjects with mild-to-moderate atopic dermatitis","volume":"12","author":"Park","year":"2020","journal-title":"Toxicol Environ Health Sci"},{"key":"10.1016\/j.jaci.2023.08.029_bib133","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cpt.1401","article-title":"Pharmacokinetics, safety, and tolerability of tezepelumab (AMG 157) in healthy and atopic dermatitis adult subjects","volume":"106","author":"Parnes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jaci.2023.08.029_bib134","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2133.2002.04833.x","article-title":"A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis","volume":"147","author":"Paul","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1034\/j.1399-3038.2001.012003154.x","article-title":"Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study","volume":"12","author":"Pei","year":"2001","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib136","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0248-8663(86)80051-0","article-title":"Value of Allerglobulin in the treatment of atopic dermatitis in children and young adults. A\u00a0double-blind randomized study [in French]","volume":"7","author":"Pons-Guiraud","year":"1986","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.jaci.2023.08.029_bib137","first-page":"85","article-title":"Effectiveness of montelukast in the treatment of atopic dermatitis","volume":"15","author":"Rahman","year":"2006","journal-title":"Mymensingh Med J"},{"key":"10.1016\/j.jaci.2023.08.029_bib138","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib139","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib141","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(00)05114-X","article-title":"Narrow-band ultraviolet B and broad-band ultraviolet A\u00a0phototherapy in adult atopic eczema: a randomised controlled trial","volume":"357","author":"Reynolds","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib142","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A\u00a0antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib143","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study","volume":"177","author":"Saeki","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib144","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.2009.09561.x","article-title":"Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial","volume":"162","author":"Schmitt","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib146","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","article-title":"Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)","volume":"87","author":"Shi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib147","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2021.07.036","article-title":"Upadacitinib plus topical corticosteroids in atopic dermatitis: week 52 AD Up study results","volume":"149","author":"Silverberg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib148","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib149","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib150","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib151","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib152","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib153","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)","volume":"85","author":"Simpson","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib154","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jid.2018.10.043","article-title":"A phase 2 randomized trial of apremilast in patients with atopic dermatitis","volume":"139","author":"Simpson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib155","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib156","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib157","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib158","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A\u00a0randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib159","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib161","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0190-9622(94)70068-0","article-title":"A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis","volume":"30","author":"Stiller","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib162","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/CCID.S146760","article-title":"Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis","volume":"10","author":"Tan","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib163","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib164","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bjd.15905","article-title":"Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial","volume":"178","author":"Tsianakas","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib165","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"van Joost","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib166","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaad.2004.12.011","article-title":"Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double-blind, placebo-controlled trial","volume":"53","author":"Veien","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib167","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s001050050860","article-title":"Phototherapy in severe atopic dermatitis. Comparison between current UVA1 therapy, UVA1 cold light and combined UVA-UVB therapy [in German]","volume":"50","author":"von Kobyletzki","year":"1999","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaci.2023.08.029_bib168","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/0001555570323329","article-title":"Antipruritic effect of oral cyclosporin A\u00a0in atopic dermatitis","volume":"70","author":"Wahlgren","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib169","article-title":"A combined responder analysis of tradipitant demonstrates significant improvements in itch and disease severity","volume":"81","author":"Welsh","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib170","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/jdv.17090","article-title":"Neurokinin-1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial","volume":"35","author":"Welsh","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.08.029_bib171","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.jaci.2018.07.047","article-title":"Efficacy and safety of the histamine H(4) receptor antagonist ZPL-3893787 in patients with atopic dermatitis","volume":"143","author":"Werfel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib172","doi-asserted-by":"crossref","first-page":"AB322","DOI":"10.1016\/j.jaci.2021.12.032","article-title":"Effect of benralizumab on skin responses to intradermal allergen challenge in patients with moderate-to-severe atopic dermatitis","volume":"149","author":"Whetstone","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib173","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/archderm.1978.01640210009002","article-title":"Levamisole therapy in atopic dermatitis: randomized double-blind evaluation","volume":"114","author":"White","year":"1978","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib174","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1365-2133.2005.06674.x","article-title":"Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial","volume":"152","author":"Wolff","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib175","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib176","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib177","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib178","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mjd.2001.111352","article-title":"The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis","volume":"44","author":"Yanase","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib179","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib180","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","article-title":"Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial","volume":"22","author":"Zhao","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"suppl\u00a048","key":"10.1016\/j.jaci.2023.08.029_bib181","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2133.1996.tb00704.x","article-title":"The long-term safety and efficacy of cyclosporin in severe refractory atopic dermatitis: a comparison of two dosage regimens","volume":"135","author":"Zonneveld","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib182","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","article-title":"The development methods of official GRADE articles and requirements for claiming the use of GRADE\u2014a statement by the GRADE guidance group","volume":"159","author":"Schunemann","year":"2023","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jaci.2023.08.029_bib183","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jaci.2022.07.023","article-title":"Topical corticosteroids for chronic rhinosinusitis with nasal polyposis: GRADE systematic review and network meta-analysis","volume":"150","author":"Bognanni","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib184","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.08.029_bib185","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/bmj.316.7132.690","article-title":"Interpreting treatment effects in randomised trials","volume":"316","author":"Guyatt","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.08.029_bib186","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-8-116","article-title":"Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units","volume":"8","author":"Johnston","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jaci.2023.08.029_bib187","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jaci.2012.08.002","article-title":"IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization","volume":"131","author":"Chu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.08.029_bib188","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1016\/j.jaip.2022.08.033","article-title":"Boxed warnings and off-label use of allergy medications: risks, benefits, and shared decision making","volume":"10","author":"Greiwe","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.08.029_bib189","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.08.029_bib190","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.08.029_bib191","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The\u00a0effects\u00a0of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.08.029_bib192","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2023.08.029_bib193","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaad.2022.05.031","article-title":"Lack of comparative evidence and conflicted commentorials in the early publication profiles of medications","volume":"88","author":"Steele","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.08.029_bib194","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jaad.2021.06.002","article-title":"New topical treatments for atopic dermatitis: active comparators are needed","volume":"85","author":"Williams","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923011120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923011120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:44:56Z","timestamp":1758793496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923011120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":194,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0091674923011120"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.08.029","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}